Trials / Completed
CompletedNCT06408753
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
Plasma Biomarker in Predicting Response and Toxicity in Hepatocellular Carcinoma Patients Treated With Checkpoint Inhibitors With or Without Sterotatic Body Radiotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective study to investigate the biomarkers in predicting treatment outcome and toxicity in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors with or without stereotactic body radiotherapy (SBRT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | sterotatic body radiotherapy | checkpoint inhibitors with or without sterotatic body radiotherapy |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2023-11-30
- Completion
- 2024-03-27
- First posted
- 2024-05-10
- Last updated
- 2024-05-10
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06408753. Inclusion in this directory is not an endorsement.